Alpha 2.0
Login Register
» Authors » Constantijn Halkes

Constantijn Halkes

Explore the profile of Constantijn Halkes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 126
Followers 0
Related Specialties
General Surgery
Hematology
Oncology
Top 10 Co-Authors
Carlo Dufour
Mahmoud Aljurf
Simone Cesaro
Jakob Passweg
Riad El Fakih
Syed Osman Ahmed
Josu de la Fuente
Britta Hochsmann
Regis de Latour
Ali Alahmari
Published In
Bone Marrow Transplant
Clin Infect Dis
Ann Hematol
Transplant Cell Ther
Am J Hematol
Affiliations
Soon will be listed here.
Recent Articles
1.
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes
Nassani M, El Fakih R, Passweg J, Cesaro S, Alzahrani H, Alahmari A, et al.
Front Oncol . 2023 May; 13:1135160. PMID: 37223686
Bone marrow failure syndromes are a heterogeneous group of diseases. With the major advancements in diagnostic tools and sequencing techniques, these diseases may be better classified and therapies may be...
2.
Correction to: Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group and Severe...
Iftikhar R, Ahmad P, de Latour R, Dufour C, Risitano A, Chaudhri N, et al.
Bone Marrow Transplant . 2021 Dec; 57(2):331. PMID: 34931011
No abstract available.
3.
Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic...
Alotaibi H, Aljurf M, de Latour R, Alfayez M, Bacigalupo A, El Fakih R, et al.
Transplant Cell Ther . 2021 Oct; 28(2):105.e1-105.e7. PMID: 34649020
Idiopathic aplastic anemia is a rare and life-threatening disorder, and hematopoietic stem cell transplantation (HSCT) from a matched sibling donor (MSD) is the standard treatment strategy for young patients. Alternative...
4.
Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia...
Iftikhar R, Ahmad P, de Latour R, Dufour C, Risitano A, Chaudhri N, et al.
Bone Marrow Transplant . 2021 May; 56(10):2518-2532. PMID: 34011966
Aplastic anemia is a relatively rare but potentially fatal disorder, with a reported higher incidence in developing countries in comparison to the West. There are significant variations in epidemiological as...
5.
Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation...
Elgohary G, El Fakih R, de Latour R, Risitano A, Marsh J, Schrezenmeier H, et al.
Bone Marrow Transplant . 2020 Apr; 55(10):1906-1917. PMID: 32346079
Aplastic anemia (AA) is a serious hematological disorder, which is solely cured by hematopoietic stem cell transplantation (HSCT). Haploidentical HSCT is an emerging modality with encouraging outcomes in several blood...
6.
Allogeneic stem cell transplantation for acquired pure red cell aplasia
Halkes C, de Wreede L, Knol C, Simand C, Aljurf M, Tbakhi A, et al.
Am J Hematol . 2019 Aug; 94(11):E294-E296. PMID: 31396977
No abstract available.
7.
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
de Witte T, Suciu S, Meert L, Halkes C, Selleslag D, Bron D, et al.
Ann Hematol . 2015 Sep; 94(12):1981-9. PMID: 26410352
The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated...
8.
Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the...
Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly J, van der Velden W, et al.
Clin Infect Dis . 2013 Jun; 57(6):794-802. PMID: 23771985
Background:  The objective of this analysis was to investigate prognostic factors that influence the outcome of Epstein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-based treatment in the allogeneic...